Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Azurrx Biopharma Inc
(NQ:
AZRX
)
0.7938
USD
-0.0205 (-2.52%)
Official Closing Price
Updated: 7:46 PM EDT, Apr 16, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Azurrx Biopharma Inc
< Previous
1
2
3
4
5
6
Next >
BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Shareholder Letter Outlines Program Highlights, Provides Business Update
April 15, 2021
From
InvestorBrandNetwork
AzurRx BioPharma CEO Issues Letter to Shareholders
April 15, 2021
From
GlobeNewswire News Releases
BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Enters Agreement for Upcoming Phase 1b/2a Clinical Trial
April 13, 2021
From
InvestorBrandNetwork
AzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for Grade 1 Immune Checkpoint Inhibitor-Associated Colitis
April 13, 2021
Phase 1b/2a Study Expected to Begin In 2Q 2021
From
GlobeNewswire News Releases
Nonhospitalized Long-Haul Coronavirus Patients Susceptible to Cognitive Dysfunction
April 12, 2021
From
InvestorBrandNetwork
BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Initiates Phase 2 RESERVOIR Trial for Treatment of COVID-19 GI Infections
April 06, 2021
From
InvestorBrandNetwork
AzurRx BioPharma Initiates Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
April 06, 2021
From
GlobeNewswire News Releases
BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Key Results from Phase 2b OPTION 2 Clinical Trial
April 01, 2021
From
InvestorBrandNetwork
AzurRx BioPharma Provides Key Takeaways from Phase 2b OPTION 2 Clinical Trial Topline Results Conference Call
March 31, 2021
From
GlobeNewswire News Releases
AzurRx BioPharma to Report Topline Data from Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis
March 31, 2021
AzurRx to Host Conference Call and Live Audio Webcast Today, Wednesday, March 31, 2021 at 4:30 p.m. ET
From
GlobeNewswire News Releases
Thinking about buying stock in CASI Pharmaceuticals, Windtree Therapeutics, ChargePoint Holdings, FreightCar America, or AzurRx BioPharma?
March 31, 2021
InvestorsObserver issues critical PriceWatch Alerts for CASI, WINT, CHPT, RAIL, and AZRX.
From
PR Newswire
Research Finds That Covid-19 Infection Increases Chance of Stroke Among Patients
March 30, 2021
From
InvestorBrandNetwork
BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Completes Enrollment in Phase 2 MS1819-PERT Combination Clinical Trial
March 22, 2021
From
InvestorBrandNetwork
AzurRx BioPharma Announces Completion of Enrollment in Phase 2 Clinical Trial of MS1819 in Combination with PERT in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficie
March 22, 2021
Top-line data expected in Q2 2021
From
GlobeNewswire News Releases
Lessons from the Fight Against COVID-19
March 18, 2021
From
InvestorBrandNetwork
BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Completes Enrollment in Upcoming Phase 2b Clinical Trial of Cystic Fibrosis Treatment
March 16, 2021
From
InvestorBrandNetwork
Thinking about buying stock in Sundial, FuelCell, Naked Brand, AzurRx, or General Electric?
March 16, 2021
InvestorsObserver issues critical PriceWatch Alerts for SNDL, FCEL, NAKD, AZRX, and GE.
From
PR Newswire
AzurRx BioPharma Announces Completion of Enrollment in Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis
March 16, 2021
From
GlobeNewswire News Releases
BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Participation in Emerging Growth Virtual Conference
March 10, 2021
From
InvestorBrandNetwork
AzurRx BioPharma to Present at the Maxim Group Emerging Growth Virtual Conference (March 17-18)
March 10, 2021
From
GlobeNewswire News Releases
BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Plans to Participate in 33rd Annual ROTH Conference, $10M Registered Direct Offering
March 08, 2021
From
InvestorBrandNetwork
AzurRx BioPharma Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
March 08, 2021
From
GlobeNewswire News Releases
AzurRx BioPharma to Participate in the 33rd Annual Roth Conference
March 08, 2021
AzurRx Chairman and CEO, James Sapirstein, to participate in panel discussion on potential developmental therapeutics for SARS-CoV-2 infection
From
GlobeNewswire News Releases
How Therapeutic Hypothermia Could Benefit ICU Patients
March 05, 2021
From
InvestorBrandNetwork
BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) to Participate in ‘Fireside Chat’ at Upcoming H.C. Wainwright Conference
March 02, 2021
From
InvestorBrandNetwork
AzurRx BioPharma to Participate in “Fireside Chat” at the H.C. Wainwright Global Life Sciences Conference
March 02, 2021
From
GlobeNewswire News Releases
BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Appoints New Chairman of the Board
February 24, 2021
From
InvestorBrandNetwork
AzurRx BioPharma Appoints President and CEO James Sapirstein as New Chairman of the Board of Directors
February 24, 2021
Former Chairman Edward J. Borkowski to continue as the lead independent director on the board
From
GlobeNewswire News Releases
Coronavirus Pandemic Exposes Biomedical Waste Disposal Challenge in India
February 22, 2021
From
InvestorBrandNetwork
InvestorNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Participation in Microcap Rodeo Winter Wonderland Conference
February 16, 2021
From
InvestorBrandNetwork
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.